ProQR Completes Enrollment for Next Phase of RNA Therapy for LCA10-CEP290
ProQR Therapeutics reached an important milestone by completing enrollment in the next pivotal phase of clinical trials of sepofarsen, a developing RNA therapy for treating LCA10, a form of Leber [...]